Prescient Therapeutics Ltd (PTX) - Net Assets
Based on the latest financial reports, Prescient Therapeutics Ltd (PTX) has net assets worth AU$16.97 Million AUD (≈ $12.01 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$18.48 Million ≈ $13.08 Million USD) and total liabilities (AU$1.51 Million ≈ $1.07 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Prescient Therapeutics Ltd to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$16.97 Million |
| % of Total Assets | 91.83% |
| Annual Growth Rate | 6.79% |
| 5-Year Change | -44.26% |
| 10-Year Change | -12.49% |
| Growth Volatility | 876.93 |
Prescient Therapeutics Ltd - Net Assets Trend (1989–2025)
This chart illustrates how Prescient Therapeutics Ltd's net assets have evolved over time, based on quarterly financial data. Also explore how large is Prescient Therapeutics Ltd's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Prescient Therapeutics Ltd (1989–2025)
The table below shows the annual net assets of Prescient Therapeutics Ltd from 1989 to 2025. For live valuation and market cap data, see PTX market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | AU$11.39 Million ≈ $8.06 Million |
-36.97% |
| 2024-06-30 | AU$18.07 Million ≈ $12.78 Million |
-30.71% |
| 2023-06-30 | AU$26.08 Million ≈ $18.45 Million |
+55.56% |
| 2022-06-30 | AU$16.76 Million ≈ $11.86 Million |
-17.94% |
| 2021-06-30 | AU$20.43 Million ≈ $14.45 Million |
+82.58% |
| 2020-06-30 | AU$11.19 Million ≈ $7.92 Million |
-21.88% |
| 2019-06-30 | AU$14.32 Million ≈ $10.13 Million |
+51.72% |
| 2018-06-30 | AU$9.44 Million ≈ $6.68 Million |
-19.90% |
| 2017-06-30 | AU$11.78 Million ≈ $8.34 Million |
-9.43% |
| 2016-06-30 | AU$13.01 Million ≈ $9.21 Million |
+192.38% |
| 2015-06-30 | AU$4.45 Million ≈ $3.15 Million |
-11.47% |
| 2014-06-30 | AU$5.03 Million ≈ $3.56 Million |
+381.30% |
| 2012-06-30 | AU$-1.79 Million ≈ $-1.26 Million |
-114.77% |
| 2011-06-30 | AU$-832.03K ≈ $-588.72K |
-398.40% |
| 2010-06-30 | AU$278.83K ≈ $197.29K |
+146.13% |
| 2009-06-30 | AU$-604.48K ≈ $-427.71K |
-927.46% |
| 2008-06-30 | AU$73.05K ≈ $51.69K |
-95.87% |
| 2007-06-30 | AU$1.77 Million ≈ $1.25 Million |
-12.79% |
| 2006-06-30 | AU$2.03 Million ≈ $1.43 Million |
-28.37% |
| 2005-06-30 | AU$2.83 Million ≈ $2.00 Million |
-22.19% |
| 2004-06-30 | AU$3.64 Million ≈ $2.57 Million |
+281.42% |
| 2003-06-30 | AU$953.60K ≈ $674.73K |
-34.51% |
| 2002-06-30 | AU$1.46 Million ≈ $1.03 Million |
-59.72% |
| 2001-06-30 | AU$3.61 Million ≈ $2.56 Million |
+183.14% |
| 2000-06-30 | AU$1.28 Million ≈ $903.24K |
-52.33% |
| 1999-06-30 | AU$2.68 Million ≈ $1.89 Million |
+128.29% |
| 1998-06-30 | AU$1.17 Million ≈ $830.02K |
+4720.30% |
| 1997-06-30 | AU$24.34K ≈ $17.22K |
+158.57% |
| 1996-06-30 | AU$-41.55K ≈ $-29.40K |
+68.99% |
| 1995-06-30 | AU$-134.00K ≈ $-94.81K |
-139.88% |
| 1994-06-30 | AU$336.00K ≈ $237.74K |
-38.46% |
| 1993-06-30 | AU$546.00K ≈ $386.33K |
-53.37% |
| 1992-06-30 | AU$1.17 Million ≈ $828.56K |
-29.42% |
| 1991-06-30 | AU$1.66 Million ≈ $1.17 Million |
-7.42% |
| 1990-06-30 | AU$1.79 Million ≈ $1.27 Million |
+67.32% |
| 1989-06-30 | AU$1.07 Million ≈ $757.80K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Prescient Therapeutics Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8255904000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$93.89 Million | 824.51% |
| Other Comprehensive Income | AU$1.57 Million | 13.75% |
| Total Equity | AU$11.39 Million | 100.00% |
Prescient Therapeutics Ltd Competitors by Market Cap
The table below lists competitors of Prescient Therapeutics Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Stallion Uranium Corp.
V:STUD
|
$40.19 Million |
|
DCM Shriram Industries Limited
NSE:DCMSRIND
|
$40.20 Million |
|
Enerside Energy S.A.
MC:ENRS
|
$40.20 Million |
|
JP Morgan Global Growth & Income PLC
LSE:JGGI
|
$40.20 Million |
|
Tondo Smart Ltd
TA:TNDO
|
$40.17 Million |
|
Lung Hwa Electronics Co Ltd
TW:2424
|
$40.14 Million |
|
Metacon AB
ST:META
|
$40.13 Million |
|
Jeil Technos Co.Ltd
KQ:038010
|
$40.12 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Prescient Therapeutics Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 18,067,288 to 11,387,172, a change of -6,680,116 (-37.0%).
- Net loss of 7,322,531 reduced equity.
- Other comprehensive income decreased equity by 628,100.
- Other factors increased equity by 1,270,515.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-7.32 Million | -64.31% |
| Other Comprehensive Income | AU$-628.10K | -5.52% |
| Other Changes | AU$1.27 Million | +11.16% |
| Total Change | AU$- | -36.97% |
Book Value vs Market Value Analysis
This analysis compares Prescient Therapeutics Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.82x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.00x to 3.82x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1989-06-30 | AU$11.20 | AU$0.05 | x |
| 1990-06-30 | AU$16.64 | AU$0.05 | x |
| 1991-06-30 | AU$15.27 | AU$0.05 | x |
| 1992-06-30 | AU$12.62 | AU$0.05 | x |
| 1993-06-30 | AU$5.88 | AU$0.05 | x |
| 1994-06-30 | AU$3.62 | AU$0.05 | x |
| 1995-06-30 | AU$-1.44 | AU$0.05 | x |
| 1996-06-30 | AU$-0.45 | AU$0.05 | x |
| 1997-06-30 | AU$0.26 | AU$0.05 | x |
| 1998-06-30 | AU$12.64 | AU$0.05 | x |
| 1999-06-30 | AU$19.09 | AU$0.05 | x |
| 2000-06-30 | AU$8.63 | AU$0.05 | x |
| 2001-06-30 | AU$22.18 | AU$0.05 | x |
| 2002-06-30 | AU$8.68 | AU$0.05 | x |
| 2003-06-30 | AU$5.83 | AU$0.05 | x |
| 2004-06-30 | AU$12.69 | AU$0.05 | x |
| 2005-06-30 | AU$8.09 | AU$0.05 | x |
| 2006-06-30 | AU$4.87 | AU$0.05 | x |
| 2007-06-30 | AU$3.19 | AU$0.05 | x |
| 2008-06-30 | AU$0.13 | AU$0.05 | x |
| 2009-06-30 | AU$-1.05 | AU$0.05 | x |
| 2010-06-30 | AU$0.35 | AU$0.05 | x |
| 2011-06-30 | AU$-0.89 | AU$0.05 | x |
| 2012-06-30 | AU$-1.56 | AU$0.05 | x |
| 2014-06-30 | AU$0.12 | AU$0.05 | x |
| 2015-06-30 | AU$0.09 | AU$0.05 | x |
| 2016-06-30 | AU$0.16 | AU$0.05 | x |
| 2017-06-30 | AU$0.06 | AU$0.05 | x |
| 2018-06-30 | AU$0.04 | AU$0.05 | x |
| 2019-06-30 | AU$0.06 | AU$0.05 | x |
| 2020-06-30 | AU$0.03 | AU$0.05 | x |
| 2021-06-30 | AU$0.03 | AU$0.05 | x |
| 2022-06-30 | AU$0.03 | AU$0.05 | x |
| 2023-06-30 | AU$0.04 | AU$0.05 | x |
| 2024-06-30 | AU$0.02 | AU$0.05 | x |
| 2025-06-30 | AU$0.01 | AU$0.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Prescient Therapeutics Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -64.31%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -168.09%
- • Asset Turnover: 0.30x
- • Equity Multiplier: 1.28x
- Recent ROE (-64.31%) is above the historical average (-297.24%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1989 | -8.85% | 0.00% | 0.00x | 6.32x | AU$-195.90K |
| 1990 | 12.95% | 0.00% | 0.00x | 4.65x | AU$45.60K |
| 1991 | -15.53% | 0.00% | 0.00x | 5.00x | AU$-361.70K |
| 1992 | -1.79% | 0.00% | 0.00x | 5.85x | AU$-138.10K |
| 1993 | -4.21% | 0.00% | 0.00x | 10.16x | AU$-77.60K |
| 1994 | -5.95% | 0.00% | 0.00x | 17.56x | AU$-53.60K |
| 1995 | 0.00% | 0.00% | 0.00x | 0.00x | AU$5.40K |
| 1997 | -5370.64% | 0.00% | 0.00x | 6.65x | AU$-1.31 Million |
| 1998 | -87.89% | 0.00% | 0.00x | 1.05x | AU$-1.15 Million |
| 1999 | -53.21% | 0.00% | 0.00x | 1.04x | AU$-1.69 Million |
| 2000 | -189.50% | -889.34% | 0.20x | 1.08x | AU$-2.55 Million |
| 2001 | -63.44% | -322.05% | 0.17x | 1.18x | AU$-2.65 Million |
| 2002 | -181.80% | -608.51% | 0.23x | 1.31x | AU$-2.79 Million |
| 2003 | -328.75% | -2035.11% | 0.09x | 1.71x | AU$-3.23 Million |
| 2004 | -108.96% | -2264.57% | 0.04x | 1.14x | AU$-4.33 Million |
| 2005 | -141.31% | -281.62% | 0.34x | 1.48x | AU$-4.28 Million |
| 2006 | -228.16% | -2212.92% | 0.06x | 1.83x | AU$-4.83 Million |
| 2007 | -150.86% | -172.85% | 0.48x | 1.84x | AU$-2.84 Million |
| 2008 | -2427.04% | -340.31% | 0.30x | 23.96x | AU$-1.78 Million |
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | AU$-1.29 Million |
| 2010 | -668.51% | 0.00% | 0.00x | 5.62x | AU$-1.89 Million |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | AU$-1.28 Million |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | AU$-1.71 Million |
| 2014 | -25.80% | -15928.47% | 0.00x | 1.05x | AU$-1.80 Million |
| 2015 | -47.94% | -5337.44% | 0.01x | 1.10x | AU$-2.58 Million |
| 2016 | -13.48% | -16387.72% | 0.00x | 1.06x | AU$-3.06 Million |
| 2017 | -21.79% | -1544.72% | 0.01x | 1.04x | AU$-3.75 Million |
| 2018 | -27.27% | -273.90% | 0.09x | 1.06x | AU$-3.52 Million |
| 2019 | -26.52% | -5265.88% | 0.00x | 1.05x | AU$-5.23 Million |
| 2020 | -29.68% | -322.74% | 0.09x | 1.08x | AU$-4.44 Million |
| 2021 | -20.31% | -350.13% | 0.06x | 1.03x | AU$-6.19 Million |
| 2022 | -30.53% | -270.88% | 0.11x | 1.05x | AU$-6.79 Million |
| 2023 | -26.86% | -288.51% | 0.09x | 1.08x | AU$-9.61 Million |
| 2024 | -45.60% | -221.93% | 0.18x | 1.13x | AU$-10.04 Million |
| 2025 | -64.31% | -168.09% | 0.30x | 1.28x | AU$-8.46 Million |
Industry Comparison
This section compares Prescient Therapeutics Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $6,848,959
- Average return on equity (ROE) among peers: -317.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Prescient Therapeutics Ltd (PTX) | AU$16.97 Million | -8.85% | 0.09x | $40.18 Million |
| Adalta Ltd (1AD) | $705.89K | -185.28% | 0.37x | $8.12 Million |
| Algorae Pharmaceuticals Ltd (1AI) | $8.43 Million | -80.40% | 0.15x | $20.04 Million |
| ACRUX Ltd (ACR) | $3.28 Million | -177.05% | 1.74x | $3.49 Million |
| Actinogen Medical Ltd (ACW) | $346.99K | -440.69% | 0.34x | $103.45 Million |
| Argenica Therapeutics Ltd (AGN) | $18.40K | -2084.05% | 19.53x | $15.45 Million |
| Arovella Therapeutics Ltd (ALA) | $15.99 Million | -12.83% | 0.27x | $66.62 Million |
| Anatara Lifesciences Ltd (ANR) | $-280.65K | 0.00% | 0.00x | $1.57 Million |
| Alterity Therapeutics Ltd (ATH) | $31.37 Million | -24.64% | 0.08x | $80.80 Million |
| Amplia Therapeutics Ltd (ATX) | $5.98 Million | -67.99% | 0.37x | $54.45 Million |
| Avecho Biotechnology Ltd (AVE) | $2.65 Million | -99.27% | 0.26x | $31.19 Million |
About Prescient Therapeutics Ltd
Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of haematological and solid cancers in Australia. Its lead drug candidate is PTX-100, a first in class targeted therapy which can disrupt the RAS family pathway by inhibiting the prenylation action of the enzyme GGT-1. The company was formerly known as Virax Holdings Limited and changed its name to… Read more